Clinical trial
A Randomized, Double-Blind, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Different Doses of a Lyophilized Herpes Zoster Virus mRNA Vaccine in Adults Aged 40 Years and Older
NCT07400003 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Different Doses of a Lyophilized Herpes Zoster Virus mRNA Vaccine in Adults Aged 40 Years and Older
- Lead sponsor
- Sinovac Biotech Co., Ltd
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- January 6, 2026
- Completion date
- April 30, 2027
- Enrollment
- 519 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
herpes zoster, mrna vaccine